
Ryzodeg Penfill100 E/U/ml
Novo Nordisk
Insulin Degludec + Insulin Aspart Premixed is indicated to improve glycemic control in adults and pediatric patients (1 year of age and older) with diabetes mellitus who require both basal…
Insulin Degludec + Insulin Aspart Premixed is indicated to improve glycemic control in adults and pediatric patients (1 year of age and older) with diabetes mellitus who require both basal (background) and prandial (mealtime) insulin coverage.
| Indication | Evidence Strength | Notes |
|---|---|---|
| Type 1 diabetes mellitus, adults and children ≥1 year | Established / approved use | Used as part of a basal-bolus regimen; individualized titration required |
| Type 2 diabetes mellitus, adults and children ≥1 year, inadequately controlled on other therapy | Established / approved use | May be used alone or with other antidiabetic agents (e.g., metformin) under medical supervision |
| Diabetic ketoacidosis | Not indicated | Insulin Degludec + Insulin Aspart Premixed is not appropriate for treatment of diabetic ketoacidosis; short-acting IV insulin is required |
Insulin Degludec + Insulin Aspart Premixed is not recommended in pediatric patients who require a total daily insulin dose of less than 5 units, because of imprecise dosing at very low volumes.
The dose of Insulin Degludec + Insulin Aspart Premixed must be individualized and titrated by a healthcare provider based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. There is no fixed universal starting dose applicable to all patients.
| Population | Typical Starting Approach |
|---|---|
| Adults with type 1 diabetes, insulin-naïve | Approximately one-third to one-half of the total daily insulin dose, given with the largest meal(s); remainder of prandial needs covered by separate rapid-acting insulin as required |
| Adults with type 2 diabetes, insulin-naïve | Approximately 10 units once daily with a main meal; adjust based on glycemic response |
| Adults switching from another insulin regimen | Dose determined individually by physician; more frequent glucose monitoring recommended during transition |
| Pediatric patients ≥1 year (established on insulin) | Often started at a reduced percentage (e.g., around 80%) of the prior total daily insulin dose to minimize hypoglycemia risk, then titrated |
Doses are typically adjusted every 3–4 days based on blood glucose patterns, under physician guidance. Do not adjust the dose without medical advice.
The most common and most serious adverse reaction associated with Insulin Degludec + Insulin Aspart Premixed is hypoglycemia (see Precautions and Warnings for full discussion).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.